Physician profile
Nayf Edrees
NPI 1346472735
$20,917.22
in general payments reported to CMS, 2019-2025
9 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $437 · 2020: $5,204 · 2021: $14K · 2022: $1,400.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Global Blood Therapeutics, INC. | $18,656.70 | 2020-2021 | |
| Fresenius Kabi USA, LLC | $1,400.00 | 2022 | |
| Swedish Orphan Biovitrum Ab | $409.08 | 2020 | |
| Genzyme Corporation | $375.00 | 2019 | |
| Novartis Pharmaceuticals Corporation | $24.11 | 2019 | |
| Csl Behring | $20.80 | 2019 | |
| Emmaus Medical, INC. | $16.83 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $14.70 | 2020 |
1 company reported research payments only; those appear in the research section below.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nayf Edrees listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.